In contrast to the potential therapeutic benefits of GCN2 inhibition or deletion in cancer, active GCN2 is required for a proper response to infection (Philips and Khan, 2021; Tomé, 2021; Zhao et al., 2023). This evidence concerns the gene EIF2AK4 and cancer.